bizarMD Profile
bizarMD

@BizarMd

Followers
969
Following
1K
Media
59
Statuses
654

Medical oncologist studying the intersection of cancer genomics, immunology and metastasis. https://t.co/uP5TGrYD7Z

New York, NY
Joined October 2018
Don't wanna be here? Send us removal request.
@BizarMd
bizarMD
1 month
Brilliant work. Necrosis is no longer just a non-specific process but active and NET pro-metastatic….
@megeblad
Mikala Egeblad
1 month
Proud to share @niseto’s (new PI @TheCrick) paper:.As a postdoc (@CSHL/@HopkinsMedicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. @JHU_BDP @Nature.
0
1
12
@BizarMd
bizarMD
2 months
RT @CureMelanoma: For this week’s #MRFResearchWednesday, we’re spotlighting 2025 Medical Student Grant Awardee @Zwalsh96 of @ColumbiaMed, w….
0
4
0
@grok
Grok
20 days
Introducing Grok Imagine.
2K
4K
28K
@BizarMd
bizarMD
2 months
RT @CellCellPress: Now online! Scalable generation and functional classification of genetic variants in inborn errors of immunity to accel….
0
7
0
@BizarMd
bizarMD
2 months
RT @zwalsh96: Thrilled to share the latest work from my PhD in the @BizarMd group! This has been a dream MD/PhD project, culminating in dat….
0
9
0
@BizarMd
bizarMD
2 months
I am extremely grateful for support from @columbiacancer Human Tissue Immunology and Immunotherapy Initiative (HTI3) @PharmingGroupNV @NIH @NCICancerCtrl @CancerResearch.
0
0
3
@BizarMd
bizarMD
2 months
This was a big team effort with many folks from my lab @FrangiehChris @NeehaKothapalli @JCA_Melms Clarissa Heck & many more. Grateful for a fantastic collaboration with disease experts @joshuamilner2 @123456789Dusan.
1
0
3
@BizarMd
bizarMD
2 months
This work has already impacted care: a patient was treated with leniolisib based directly on our variant classification. And it serves as a useful blueprint for other IEIs and beyond . Stay tuned!.
1
0
3
@BizarMd
bizarMD
2 months
How relevant are these variants? By integrating our screen with All of Us (>600K genomes) and an IEI cohort (>8K pts), we found 100+ carriers enriched for immune disease phenotypes. So the disease could be magnitudes of order more common than we thought.
Tweet media one
1
0
1
@BizarMd
bizarMD
2 months
Some PIK3R1 variants were only partially responsive to leniolisib. We uncovered combo therapies (e.g. leniolisib + mTORi) that restored suppression in both edited cells and patient samples.
Tweet media one
1
0
1
@BizarMd
bizarMD
2 months
We validated screen results and phenotypes using T cells from two APDS patients with variants mapping to structural GOF hotspots flagged by our screen, directly linking screen data to real disease.
Tweet media one
1
1
4
@BizarMd
bizarMD
2 months
T cells with newly identified GOF variants showed hyperactivation, exhaustion & transcriptional changes—mirroring APDS patient cells. Like patients, they also responded to leniolisib.
Tweet media one
1
0
1
@BizarMd
bizarMD
2 months
The result: reliable recovery of known pathogenic variants, along with dozens of novel GOF variants previously unstudied or classified as VUS
Tweet media one
1
0
1
@BizarMd
bizarMD
2 months
Usuually these are tested one at a time . Insteadl we used CRISPR base editing to engineer thousands of PIK3CD/PIK3R1 variants in primary T cells, and mapped these to pAKT/pS6—a readouts used to guide variant classification in real patients.
Tweet media one
1
0
1
@BizarMd
bizarMD
2 months
NGS often reveals variants of uncertain significance (VUS), stalling care and precision therapy. In Activated PI3Kδ Syndrome (APDS), an inborn error of immunity, PI3Kδ inhibitor leniolisib is effective but only approved for pts w/ proven pathogenic GOF variants. .
1
0
1
@BizarMd
bizarMD
2 months
Excited to share a new paper: @CellCellPress: a framework to accelerate variant classification, diagnosis & treatment of immune disorders & genetic disorders more broadly. Led by superstar, juggernaut & future dermatologist @zwalsh96
Tweet media one
3
14
43
@BizarMd
bizarMD
4 months
Congrats, Neil! We will miss you at Columbia but happy for you! Great opportunity for your outstanding work.
@NeilVasan
Neil Vasan
4 months
I am thrilled to have joined @nyulangone @Perlmutter_CC on May 1, 2025 as Assistant Professor and Director of Translational Research in Breast Cancer. Excited to launch the next chapter of our lab’s work in NYC and accelerate impact for patients with breast cancer.
1
1
5
@BizarMd
bizarMD
4 months
Proud of you, @zwalsh96. Thank you @ClinImmSoc for recognizing your boundless talent and inviting you to give a major talk. What an incredible achievement. Excited for the next chapter in your work (well, I kinda know, so even more excited!).
@zwalsh96
Zach Walsh
4 months
Truly amazing experience to get to present our variant reclassification work at the opening plenary session of @ClinImmSoc 2025. Couldn’t have asked for a better audience for this work, as evidenced by so many insightful questions and conversations!
Tweet media one
0
0
8
@BizarMd
bizarMD
4 months
It was a tremendous honor to receive this important Award on behalf of my laboratory. Thank you @the_asci.
@the_asci
ASCI
4 months
ASCI member @BizarMd @Columbia presenting the Seldin~Smith Award Lecture: Tumor-immune interplay during metastatic reactivation from dormancy @JointMeeting.#JointMeeting2025
Tweet media one
2
1
27
@BizarMd
bizarMD
4 months
Congrats Emily and Elena!! Beautiful study that’s really foundational to neural-like states in metastasis.
@bernstein_lab
Emily Bernstein Lab
4 months
🎉 Excited to share the latest work from our lab uncovering an unappreciated role for the SWI/SNF PBAF complex at repressive chromatin🧬.Led by @ElenaGrossi8 and now published @MolecularCell.
0
1
6
@BizarMd
bizarMD
5 months
0
0
1